Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a Phase 3 clinical study titled A ...
Shanghai Pharmaceuticals Holding Co Class H (($SHPMF)) announced an update on their ongoing clinical study. Shanghai Pharmaceuticals Holding Co.
JSKN022 innovatively combines immuno-oncology (IO) mechanisms with ADC approaches, utilizing Alphamab Oncology's proprietary glycan-specific conjugation platform and linker-payload (Alphatecan) to ...
MedPage Today on MSN
Checkpoint Blockade Finally Breaks Through in Ovarian Cancer
BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...
PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...
Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic ...
The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback